Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Clinical Data in $252 million deal with CombinatoRx to develop novel cancer therapy
September 2009
SHARING OPTIONS:

NEWTON, Mass.Clinical Data Inc. announced in August a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers. Under the agreement, Clinical Data licensed its highly selective adenosine A2A agonist, ATL313, to CombinatoRx in exchange for the potential to receive up to $252 million in clinical, regulatory and commercial milestones, as well as royalties on product sales. CombinatoRx will be responsible for the preclinical and clinical development of ATL313 to potentially treat B-cell malignancies. Clinical Data also retains a co-development option, which is exercisable after review of any Phase IIa study results.          

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.